This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Buserelin nasal 150 microgram


Aqueous nasal spray containing 150 micrograms buserelin per actuation

Drugs List

  • buserelin 150microgram nasal spray
  • SUPRECUR 150microgram nasal spray
  • Therapeutic Indications


    Pituitary desensitisation in preparation for ovulation induction regimes
    Treatment of endometriosis



    Total recommended daily dose is 900 micrograms, given as a single 150 microgram dose spray in each nostril 3 times a day, starting on days 1 or 2 of menstruation. Intervals between doses should be as evenly spaced as possible.

    The total duration of therapy should not exceed 6 months and should not be repeated.

    A repeated course of treatment must only be administered after a careful review of the risk/benefit ratio by the attending physician since the possibility of additive effects on bone mass (reduction in bone mass) cannot be excluded.

    Pituitary desensitisation before induction of ovulation by gonadotrophins
    Total recommended daily dose is 600 micrograms, given as a single 150 microgram dose spray in one nostril 4 times a day. Intervals between doses should be as evenly spaced as possible throughout the waking hours.

    Treatment should start in the early follicular phase (day 1) or, provided the existence of an early pregnancy has been excluded, in the mid-luteal phase (day 21).

    Treatment should continue until down-regulation is achieved (serum estradiol less than 50 nanograms/litre and serum progesterone less than 1 microgram/litre). This will usually take between 2 and 3 weeks.

    Dosage should be adjusted according to individual response, and occasionally may need to be increased up to 1,200 micrograms (one spray in each nostril 4 times a day) to achieve these levels.

    Once down-regulation has been achieved, stimulation with gonadotrophin is commenced whilst the dose of buserelin is maintained.

    When the appropriate stage of follicular development is reached, the gonadotrophin and buserelin are both stopped, and chorionic gonadotrophin is then given to induce ovulation.

    Additional Dosage Information

    Absorption takes place through the nasal mucous membranes, and is reliable even if the patient has a cold or rhinitis. In these cases the nose should be cleared prior to administering the dose. If nasal decongestants are being used, they must be used at least 30 minutes after using buserelin.


    Children under 18 years
    Postmenopausal females
    Long QT syndrome
    Torsade de pointes
    Undiagnosed gynaecological haemorrhage

    Precautions and Warnings

    Family history of long QT syndrome
    Diabetes mellitus
    Electrolyte imbalance
    History of torsade de pointes
    Metabolic bone disease
    Polycystic ovarian syndrome

    Correct electrolyte disorders before treatment
    Advise ability to drive/operate machinery may be affected by side effects
    Treatment to be initiated and supervised by a specialist
    Contains benzalkonium chloride
    Do not use other nasal preparations until 30 minutes after treatment
    Exclude pregnancy prior to initiation of treatment
    Consider monitoring ECG in patients at risk of QT prolongation
    Monitor blood pressure in hypertensive patients
    Monitor bone status in long term therapy
    Monitor closely patient with depression
    Monitor serum electrolytes
    Monitor stimulation cycle
    Advise patient to report any new or worsening depression/suicidal ideation
    Ovarian cysts can develop in the initial treatment phase
    Ovarian hyperstimulation syndrome can occur
    Pregnancy confirmed: Discontinue this medication
    Endometriosis: 6 months maximum duration of treatment. Do not repeat course
    Endometriosis: There is a risk of ovulation if treatment is interrupted
    Female: If contraception appropriate, non-hormonal methods required
    Changes in menstrual bleeding patterns should be expected

    In patients being treated for endometriosis a menstruation-like bleed often occurs during the first few weeks of treatment. In some patients receiving continuous treatment courses, breakthrough bleeding may occur. The recovery of pituitary-gonadal function usually occurs within 8 weeks of discontinuing treatment.

    The combined use of buserelin and gonadotrophins may bear a higher risk of ovarian hyperstimulation syndrome (OHSS) than with gonadotrophins alone. Monitor the stimulation cycle carefully to identify patients at risk of developing OHSS, the addition of hCG should be withheld if necessary.

    Symptoms of OHSS include abdominal pain, abdominal tension, increased abdominal girth, ovarian cysts, nausea, vomiting, ovarian enlargement, dyspnoea, diarrhoea, oliguria, haemoconcentration and hypercoagulability. An acute abdomen may occur as a result of pedicle tension or rupture of the ovary. Severe OHSS may result in thromboembolic events, with the possibility of fatal outcomes.

    Pregnancy and Lactation


    Buserelin is contraindicated in pregnancy.

    Pregnancy should be excluded before starting treatment.

    Discontinue treatment immediately if pregnancy occurs.

    Animal reproductive studies have shown foetal toxicity in rats at very high doses.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Buserelin is contraindicated in breastfeeding.

    Manufacturer advises that use should be avoided. Small amounts are secreted in breast milk although no adverse effects on the infant have been observed.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Allergic asthma with dyspnoea
    Anaphylactic shock
    Blood lipid changes
    Blurred vision
    Breakthrough bleeding
    Breast tenderness
    Changes in breast size
    Changes in libido
    Changes in scalp or body hair
    Concentration disturbances
    Contact lenses may irritate
    Decrease in bone mineral density
    Decreased glucose tolerance
    Decreased glycaemic control in diabetes
    Deterioration in blood pressure in hypertensive patients
    Disturbances of appetite
    Dry skin
    Dryness of eyes
    Elevation of liver enzymes
    Emotional lability
    Facial oedema
    Feeling of pressure behind the eyes
    Hearing disturbances
    Hot flushes
    Hypersensitivity reactions
    Increase in serum alkaline phosphatase (reversible)
    Increased sweating
    Increased thirst
    Irritation of nasal mucosa
    Lower abdominal pain
    Memory disturbances
    Musculoskeletal pain
    Nose bleeds
    Oedema of the extremities (arms and legs)
    Ovarian cysts
    Ovarian hyperstimulation syndrome (OHSS)
    Pituitary adenomas
    Prolongation of QT interval
    Serum bilirubin increased
    Shoulder pain
    Skin reddening
    Sleep disturbances
    Smelling disturbances
    Splitting nails
    Stomach pain
    Taste disturbances
    Vaginal discharge
    Vaginal dryness
    Vertebral and long bone fractures
    Visual disturbances
    Weight changes
    Withdrawal vaginal bleeding during early treatment phase


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: May 2016

    Reference Sources

    Joint Formulary Committee. British National Formulary. 71st ed. London: BMJ Group and Pharmaceutical Press; 2016.

    Summary of Product Characteristics: Suprecur 150 mcg Nasal Spray Solution. SANOFI. Revised February 2015.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.